The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Having more choices about the treatment of hemophilia is empowering, but it also comes with challenges, columnist Jennifer Lynne writes.

Columnist Joe MacDonald explains how holding on to rituals has gotten his family through some challenging times with chronic illness.

The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...

Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...

A woman with a severe needle phobia has described how she discharged herself from hospital – despite needing treatment to ...

Sarah, a haemophiliac, has described how her decades long terror of needles led to to life threatening situations on several ...

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or without inhibitors.

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

Campaigners are furious that payouts agreed by the Government are taking too long to reach those affected by the biggest ...

Tony Summers, whose son died from HIV and Hepatitis C, fears he will be dead before his compensation is paid.